Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Pharmacist Survey: Pharmacist Perception of Vancomycin Area Under the Curve Therapeutic Drug Monitoring.

Gregory ER, Burgess DR, Cotner SE, VanHoose JD, Flannery AH, Gardner B, Autry EB, Forster DW, Burgess DS, Wallace KL.

J Pharm Pract. 2019 Aug 18:897190019867494. doi: 10.1177/0897190019867494. [Epub ahead of print]

PMID:
31422738
2.

Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin.

Rutter WC, Hall RG, Burgess DS.

Am J Health Syst Pharm. 2019 Aug 1;76(16):1211-1217. doi: 10.1093/ajhp/zxz120.

PMID:
31369116
3.
4.

Evaluation of the BD Phoenix automated system for determining antimicrobial susceptibility against carbapenem-resistant Enterobacteriaceae compared with broth microdilution.

Haffler ZJ, Kulengowski B, Ribes JA, Burgess DS.

Int J Antimicrob Agents. 2019 Aug;54(2):249-254. doi: 10.1016/j.ijantimicag.2019.05.002. Epub 2019 May 7.

PMID:
31071467
5.

Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned.

Gregory ER, Burgess DR, Cotner SE, VanHoose JD, Flannery AH, Gardner B, Autry EB, Forster DW, Burgess DS, Wallace KL.

J Pharm Pract. 2019 Mar 10:897190019834369. doi: 10.1177/0897190019834369. [Epub ahead of print]

PMID:
30852937
6.

Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.

Nolt VD, Pijut KD, Autry EB, Williams WC, Burgess DS, Burgess DR, Arora V, Kuhn RJ.

Pediatr Pulmonol. 2019 Jan;54(1):33-39. doi: 10.1002/ppul.24194. Epub 2018 Dec 3.

PMID:
30507069
7.

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.

Kulengowski B, Clark JA, Burgess DS.

Diagn Microbiol Infect Dis. 2019 Apr;93(4):372-375. doi: 10.1016/j.diagmicrobio.2018.10.020. Epub 2018 Nov 10.

PMID:
30514595
8.

Staggering the administration of polymyxin B and meropenem in time-kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs.

Kulengowski B, Clark JA, Burgess DS.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):261-264. doi: 10.1016/j.diagmicrobio.2018.09.014. Epub 2018 Oct 4.

PMID:
30344066
9.

Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae.

Kulengowski B, Rutter WC, Campion JJ, Lee GC, Feola DJ, Burgess DS.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):262-266. doi: 10.1016/j.diagmicrobio.2018.06.013. Epub 2018 Jun 22.

PMID:
30098852
10.

Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.

Rutter WC, Burgess DS.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00264-18. doi: 10.1128/AAC.00264-18. Print 2018 Jul.

11.

Polymyxin B Etest® compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of polymyxin B MICs.

Kulengowski B, Ribes JA, Burgess DS.

Clin Microbiol Infect. 2019 Jan;25(1):92-95. doi: 10.1016/j.cmi.2018.04.008. Epub 2018 Apr 16.

PMID:
29674129
12.

Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.

Cotner SE, Rutter WC, Burgess DR, Wallace KL, Martin CA, Burgess DS.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00871-17. doi: 10.1128/AAC.00871-17. Print 2017 Oct.

13.

Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae.

Kulengowski B, Campion JJ, Feola DJ, Burgess DS.

J Antibiot (Tokyo). 2017 Aug;70(9):974-978. doi: 10.1038/ja.2017.73. Epub 2017 Jul 5. No abstract available.

PMID:
28676713
14.

Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.

Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00314-17. doi: 10.1128/AAC.00314-17. Print 2017 Apr. No abstract available.

15.

Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Rutter WC, Burgess DS.

Pharmacotherapy. 2017 May;37(5):593-598. doi: 10.1002/phar.1918. Epub 2017 Apr 20.

16.

Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis.

Rutter WC, Burgess DR, Talbert JC, Burgess DS.

J Hosp Med. 2017 Feb;12(2):77-82. doi: 10.12788/jhm.2684.

17.

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

Crass RL, Rutter WC, Burgess DR, Martin CA, Burgess DS.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02329-16. doi: 10.1128/AAC.02329-16. Print 2017 Apr.

18.

Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.

Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02089-16. doi: 10.1128/AAC.02089-16. Print 2017 Feb. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

19.

Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.

Rutter WC, Burgess DR, Burgess DS.

Microb Drug Resist. 2017 Jan;23(1):51-55. doi: 10.1089/mdr.2016.0048. Epub 2016 Jun 21.

PMID:
27326758
20.

Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.

Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS.

J Cyst Fibros. 2016 Sep;15(5):660-3. doi: 10.1016/j.jcf.2016.04.002. Epub 2016 May 4.

21.

Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy.

Tennant SJ, Burgess DR, Rybak JM, Martin CA, Burgess DS.

Antibiotics (Basel). 2015 Dec 11;4(4):643-52. doi: 10.3390/antibiotics4040643.

22.

Optimizing postgraduate year 3 training.

Flannery AH, Adams VR, Burgess DS.

Am J Health Syst Pharm. 2014 Nov 15;71(22):1924-5. doi: 10.2146/ajhp140552. No abstract available.

PMID:
25349234
23.

Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.

Lee GC, Lawson KA, Burgess DS.

Ann Pharmacother. 2013 Sep;47(9):1115-21. doi: 10.1177/1060028013503120.

PMID:
24259725
24.

Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae.

Lee GC, Burgess DS.

J Clin Med Res. 2013 Apr;5(2):97-100. doi: 10.4021/jocmr1220w. Epub 2013 Feb 25.

25.

Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.

Lee GC, Burgess DS.

Ann Clin Microbiol Antimicrob. 2012 Dec 13;11:32. doi: 10.1186/1476-0711-11-32. Review.

26.

In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.

Le J, McKee B, Srisupha-Olarn W, Burgess DS.

J Clin Med Res. 2011 May 19;3(3):106-10. doi: 10.4021/jocmr551w.

27.

Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.

Burgess DS, Slain D, Mohr J, Wong-Beringer A, Destache C, Suda K.

Clin Infect Dis. 2010 Sep 15;51(6):753; author reply 754-5. doi: 10.1086/655957. No abstract available.

PMID:
20731568
28.

Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.

Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, Ruiz JL, Burgess DS.

Clin Ther. 2010 Feb;32(2):293-9. doi: 10.1016/j.clinthera.2010.02.006.

PMID:
20206787
29.

Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California.

Le J, Castanheira M, Burgess DS, McKee B, Iqbal R, Jones RN.

J Clin Microbiol. 2010 Feb;48(2):623-5. doi: 10.1128/JCM.02397-09. Epub 2009 Dec 23.

30.

Curbing resistance development: maximizing the utility of available agents.

Burgess DS.

J Manag Care Pharm. 2009 Jun;15(5 Suppl):S5-9. Review.

PMID:
19505173
32.

Bugs versus drugs: addressing the pharmacist's challenge.

Burgess DS, Rapp RP.

Am J Health Syst Pharm. 2008 May 1;65(9 Suppl 2):S4-15. doi: 10.2146/ajhp080075.

PMID:
18436737
33.

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.

Frei CR, Wiederhold NP, Burgess DS.

J Antimicrob Chemother. 2008 Mar;61(3):621-8. doi: 10.1093/jac/dkm536. Epub 2008 Feb 4.

34.

Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.

Cota JM, Grabinski JL, Talbert RL, Burgess DS, Rogers PD, Edlind TD, Wiederhold NP.

Antimicrob Agents Chemother. 2008 Mar;52(3):1144-6. Epub 2007 Dec 17.

36.

Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit.

Cadena J, Taboada CA, Burgess DS, Ma JZ, Lewis JS 2nd, Freytes CO, Patterson JE.

Bone Marrow Transplant. 2007 Jul;40(2):151-5. Epub 2007 May 28.

PMID:
17530005
37.

Murine airway histology and intracellular uptake of inhaled amorphous itraconazole.

Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS, Johnston KP, Williams RO 3rd, Peters JI.

Int J Pharm. 2007 Jun 29;338(1-2):219-24. Epub 2007 Feb 14.

PMID:
17368772
38.

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO 3rd.

J Infect. 2007 Jul;55(1):68-74. Epub 2007 Mar 13.

PMID:
17360039
39.

Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation.

Martin CP, Talbert RL, Burgess DS, Peters JI.

Pharmacotherapy. 2007 Jan;27(1):20-6.

PMID:
17192158
40.
41.

Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.

Frei CR, Restrepo MI, Mortensen EM, Burgess DS.

Am J Med. 2006 Oct;119(10):865-71.

PMID:
17000218
43.

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP.

Antimicrob Agents Chemother. 2006 Nov;50(11):3926-8. Epub 2006 Aug 28.

44.

Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.

McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS, Talbert RL, Peters JI, Johnston KP, Williams RO 3rd.

Pharm Res. 2006 May;23(5):901-11. Epub 2006 May 5.

PMID:
16715380
45.

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO 3rd.

Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4.

47.
48.
49.

Continuous infusion beta-lactams for intensive care unit pulmonary infections.

Frei CR, Burgess DS.

Clin Microbiol Infect. 2005 May;11(5):418-21.

50.

Supplemental Content

Loading ...
Support Center